Management of pre-liver transplantation patients - Part 1

Liver Transplantation

Volumn 11, Issue 2, 2005, Pages 124-133

  Sharma, Pratima ^a   Rakela, Jorge ^b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALCOHOL; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ALPHA INTERFERON; ANTIVIRUS AGENT; AZATHIOPRINE; BILIRUBIN; CA 19-9 ANTIGEN; CREATININE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; LAMIVUDINE; MULTIVITAMIN; PEGINTERFERON; PNEUMOCOCCUS VACCINE; PREDNISONE; RIBAVIRIN; URSODEOXYCHOLIC ACID; VIRUS DNA; ZINC;

ARTICLE; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; CANCER CLASSIFICATION; CANCER RISK; CANCER SCREENING; CHEMOEMBOLIZATION; CHRONIC DISEASE; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DEPRESSION; DRUG DOSE REGIMEN; DRUG FATALITY; FERRITIN BLOOD LEVEL; GRAFT SURVIVAL; HEART DISEASE; HEMOCHROMATOSIS; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; INFLUENZA; INTERNATIONAL NORMALIZED RATIO; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; LUNG DISEASE; MEDICAL CARE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PATIENT CARE; PATIENT SELECTION; PHLEBOTOMY; PORTAL HYPERTENSION; PREOPERATIVE EVALUATION; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; SIDE EFFECT; STREPTOCOCCUS INFECTION; TREATMENT CONTRAINDICATION; ZINC DEFICIENCY;

CARCINOMA, HEPATOCELLULAR; CHOLANGITIS, SCLEROSING; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, BILIARY; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM STAGING; TISSUE AND ORGAN PROCUREMENT;

EID: 13944269592     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20353     Document Type: Article

References (65)

1. Carithers RL Jr. Liver transplantation. American Association for the Study of Liver Diseases. Liver Transpl 2000;6:122-135.
2. United Network for Organ Sharing and Organ Procurement and Transplant Network, Richmond, VA. Current U.S. waiting list for liver transplantation. In: United Network for Organ Sharing,; 2004. Available at http://www.optn.org/rptdata.asp. Accessed on July 13, 2004.
3. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997;3:628-637.
4. United Network for Organ Sharing, Richmond, VA, Allocation of liver policy. In: United Network for Organ Donation; 2002. http://www.UNOS.org/resources/policy.
5. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
6. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001;7:567-580.
7. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, terBorg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-871.
8. Sheth M, Riggs M, Patel T. Utility of the Mayo end-stage liver disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002;2:2.
9. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
10. Krowka MJ. Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemmas. Hepatology 1997;25:1282-1284.
11. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6:443-450.
12. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002;35:105-109.
13. Annual Report of U.S. Scientific Registry for Organ Transplantation and the Organ Procurement and Transplantation Network. UNOS, Richmond, VA and Division of Transplantation, Bureau of Health Resources and Services Administration, U.S. Department of Health and Human Services, Bethesda, MD, 1990. Available at http://www.unos.org.
14. Zetterman RK, Belle SH, Hoofnagle JH, Lawlor S, Wei Y, Everhart J, et al. Age and liver transplantation: a report of the Liver Transplantation Database. Transplantation 1998;66:500-506.
15. Levy MF, Somasundar PS, Jennings LW, Jung GJ, Molmenti EP, Fasola CG, et al. The elderly liver transplant recipient: a call for caution. Ann Surg 2001;233:107-113.
16. UNOS. United Network for Organ Sharing (UNOS) registry. 2002. http://www.UNOS.org.
17. Castaldo P, Langnas AN, Stratta RJ, Lieberman RP, Wood RP, Shaw BW Jr. Successful liver transplantation in a patient with a thrombosed portomesenteric system after multiple failed shunts. Am J Gastroenterol 1991;86:506-508.
18. Jr SB: Liver transplantation in patients over 60 years of age. In: Liver update: function and disease. Vol. 5. Cedar Grove, NJ: American Liver Foundation, 1992:3-4.
19. Shaw BW Jr, Wood RP, Stratta RJ, Pillen TJ, Langnas AN. Stratifying the causes of death in liver transplant recipients. An approach to improving survival. Arch Surg 1989;124:895-900.
20. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000;356:1800-1805.
21. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenteraily-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.
22. Sanchez-Quijano A, Andreu J, Gavilan F, Luque F, Abad MA, Soto B, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995;14:949-953.
23. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497.
24. Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999;15:1-4.
25. Gow PJ, Mutimer D. Liver transplantation for an HIV-positive patient in the era of highly active antiretroviral therapy. Aids 2001;15:291-292.
26. Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003;188:1412-1420.
27. Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003;9:239-247.
28. Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002;347:284-287.
29. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36:S74-S83.
30. Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003;38:1034-1042.
31. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-290.
32. Cooksley G. The importance and benefits of hepatitis A prevention in chronic liver disease patients. J Gastroenterol Hepatol 2004;19(Suppl):S17-S20.
33. Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther 2004;19:715-727.
34. Dominguez M, Barcena R, Garcia M, Lopez-Sanroman A, Nuno J. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 2000;6:440-442.
35. Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 2000;14(Suppl B):59B-62B.
36. Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 2001;7:314-320.
37. Fontana RJ, Keeffe EB, Carey W, Fried M, Reddy R, Kowdley KV, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002;8:433-439.
38. Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000;32:1145-1153.
39. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419-1427.
40. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171.
41. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
42. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001;33:1321-1328.
43. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-1119.
44. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997;25:162-166.
45. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-890.
46. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336:691-695.
47. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000;31:1005-1013.
48. Springer JE, Cole DE, Rubin LA, Cauch-Dudek K, Harewood L, Evrovski J, et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000;118:145-151.
49. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002;50(Suppl 1):i1-i9.
50. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000;95:204-207.
51. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995;108:865-869.
52. Hultcrantz R, Olsson R, Danielsson A, Jarnerot G, Loof L, Ryden BO, et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999;30:669-673.
53. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;51(Suppl 6):VI1-VI9.
54. Stiehl A. Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis. Scand J Gastroenterol Suppl 1994;204:59-61.
55. Brentnall TA, Haggitt RC, Rabinovitch PS, Kimmey MB, Bronner MP, Levine DS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996;110:331-338.
56. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95.
57. Czaja AJ. Treatment of autoimmune hepatitis. Semin Liver Dis 2002;22:365-378.
58. De Bona M, Ponton P, Ermani M, Iemmolo RM, Feltrin A, Boccagni P, et al. The impact of liver disease and medical complications on quality of life and psychological distress before and after liver transplantation. J Hepatol 2000;33:609-615.
59. Singh N, Gayowski T, Wagener MM, Marino IR. Depression in patients with cirrhosis. Impact on outcome. Dig Dis Sci 1997;42:1421-1427.
60. Muller MJ. Malnutrition in cirrhosis. J Hepatol 1995;23(Suppl 1):31-35.
61. Richardson RA, Davidson HI, Hinds A, Cowan S, Rae P, Garden OJ. Influence of the metabolic sequelae of liver cirrhosis on nutritional intake. Am J Clin Nutr 1999;69:331-337.
62. Lochs H, Plauth M. Liver cirrhosis: rationale and modalities for nutritional support - the European Society of Parenteral and Enteral Nutrition consensus and beyond. Curr Opin Clin Nutr Metab Care 1999;2:345-349.
63. Riggio O, Ariosto F, Merli M, Caschera M, Zullo A, Balducci G, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind cross-over trial. Dig Dis Sci 1991;36:1204-1208.
64. Mizock BA. Nutritional support in hepatic encephalopathy. Nutrition 1999;15:220-228.
65. American Liver Tumor Study Group - a randomized prospective multi-institutional trial of orthotopic liver transplantation or partial hepatic resection with or without adjuvant chemotherapy for hepatocellular carcinoma. Investigators Booklet and Protocol, 1998.